DDInter842 DDInter899
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludarabine
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Denileukin diftitox
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Insulin glargine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Denileukin diftitox
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Caffeine
Grepafloxacin may lead to a major life threatening interaction when taken with Encorafenib
Grepafloxacin may lead to a major life threatening interaction when taken with Insulin glargine